NK cells

Phase 2Cell therapy

SSouthwest Hospital, China

NK cells is one of 372 biologic programs targeting Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

371

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

LeukemiaActive, not recruiting

NeuroblastomaActive, not recruiting

Lung AdenocarcinomaActive, not recruiting

Myelodysplastic SyndromeActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Colorectal CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Lung CancerPhase 2

Active, not recruiting

LeukemiaPhase 1

Active, not recruiting

NeuroblastomaPhase 1

Active, not recruiting

Lung AdenocarcinomaPhase 1

Active, not recruiting

Myelodysplastic SyndromePhase 1

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

Colorectal CancerPhase 1/Phase 2

Active, not recruiting

Pancreatic CancerPhase 1/Phase 2

Active, not recruiting

Hepatocellular CarcinomaPhase 2

Active, not recruiting

Showing 10 of 14 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tykerb

GSK

Preclinical

80 2

NK cells

SSouthwest Hospital, China

Phase 2

1 3

DATROWAY

Daiichi Sankyo

Preclinical

4 4

Megace

Bristol-Myers Squibb

Preclinical

4 5

MS Contin

Merck & Co.

Preclinical

2 6

Spravato

WWim Janssens

Preclinical

2 7

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 8

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 9

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 10

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Neuroblastoma

NCT02573896

Q2 2028

Phase 1/2Not yet recruiting

Acute Myeloid Leukemia

NCT05319249

Phase 1Recruiting

Acute Myeloid Leukemia

NCT05834244

Q4 2030

Phase 1/2Not yet recruiting

Colorectal Cancer

NCT07411599

Q4 2031

Phase 1Recruiting

Natural Killer Cell

NCT04254419

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia2 trials

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT05834244·32 enrolled

Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia

Not yet recruiting·GGerman Cancer Research Center·Phase 1/2·NCT05319249·54 enrolled

Neuroblastoma2 trials

Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT02650648·85 enrolled

Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells

Active, not recruiting·NNew Approaches to Neuroblastoma Therapy Consortium·Phase 1·NCT02573896·13 enrolled

Lung Cancer1 trial

NK Cell-based Immunotherapy as Maintenance Therapy for Small-Cell Lung Cancer.

Unknown status·Jjiuwei cui·Phase 2·NCT03410368·120 enrolled

Pancreatic Cancer1 trial

Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer

Completed·FFuda Cancer Hospital, Guangzhou·Phase 1/2·NCT02718859·60 enrolled

Natural Killer Cell1 trial

Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells

Recruiting·NNationwide Children's Hospital·Phase 1·NCT04254419·18 enrolled

14 more indications

Myelodysplastic Syndrome1 trial

Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome

Unknown status·NNational University Hospital, Singapore·Phase 1·NCT02123836·20 enrolled

Colorectal Cancer1 trial

Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT07411599·28 enrolled

Hepatocellular Carcinoma1 trial

By Using Adoptive Transfer of Autologous NK Cells to Prevent Recurrence of Hepatocellular Carcinoma After Curative Therapy

Unknown status·SSouthwest Hospital, China·Phase 2·NCT02725996·140 enrolled

Myelopathy1 trial

Immunotherapy of Natural Killer(NK) Cells in Human T Lymphotropic Virus Type 1(HTLV-1) Associated Myelopathy(HAM)

Unknown status·TThe Second Affiliated Hospital of Fujian Medical University·Phase 1·NCT02961712·15 enrolled

Breast Cancer1 trial

A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020

Terminated·VVall d'Hebron Institute of Oncology·Phase 1·NCT05385705·2 enrolled

Myeloid Diseases1 trial

NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT01370213·25 enrolled

Advanced Malignancies1 trial

NK Cells Infusion for Advanced Malignancies

Unknown status·—·Phase 1·NCT03619954·50 enrolled

Lung Adenocarcinoma1 trial

Effect of NK Cell Immunotherapy on Advanced Lung Adenocarcinoma Adenocarcinoma With EGFR Mutation

Unknown status·SShenzhen Fifth People's Hospital·Phase 1·NCT03662477·10 enrolled

COVID-191 trial

NK Cells Treatment for COVID-19

Completed·HHenan Medical University·Phase 1·NCT04280224·2 enrolled

Leukemia1 trial

Adoptive Immunotherapy of High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-mismatched Natural Killer Cells

Unknown status·UUniversity of Bologna·Phase 1·NCT00799799·15 enrolled

Primary Peritoneal Cancer1 trial

Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT02118285·2 enrolled

Non-Small Cell Lung Cancer1 trial

A Clinical Research of NK Cell Infusion Combined With Chemotherapy in the Treatment of Non-small Cell Lung Cancer

Unknown status·SSouthwest Hospital, China·Phase 2·NCT02734524·104 enrolled

Immunotherapy1 trial

Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML

Terminated·TTechnische Universität Dresden·Phase 2·NCT02229266·1 enrolled

Chronic Myeloid Leukemia (CML)1 trial

Safety and the Anti- Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK-TRAIL Cytotoxicity With Bortezomib

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1·NCT00720785·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 21 trial records for NK cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NK cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NK cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Southwest Hospital, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: SSouthwest Hospital, China

NK cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2028

Q4 2030

Q4 2031

Trials by Indication[1]

Acute Myeloid Leukemia2 trials

Neuroblastoma2 trials

Lung Cancer1 trial

Pancreatic Cancer1 trial

Natural Killer Cell1 trial

Myelodysplastic Syndrome1 trial

Colorectal Cancer1 trial

Hepatocellular Carcinoma1 trial

Myelopathy1 trial

Breast Cancer1 trial

Myeloid Diseases1 trial

Advanced Malignancies1 trial

Lung Adenocarcinoma1 trial

COVID-191 trial

Leukemia1 trial

Primary Peritoneal Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Immunotherapy1 trial

Chronic Myeloid Leukemia (CML)1 trial

References

Drug Info

Quick Facts

Related News